MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
72.21
+0.39 (+0.54%)
At close: 4:02PM EDT

72.32 +0.11 (0.15%)
Pre-Market: 9:05AM EDT

Stock chart is not supported by your current browser
Previous Close71.82
Open72.15
Bid72.22 x 1800
Ask72.95 x 1800
Day's Range71.42 - 72.40
52 Week Range52.83 - 72.89
Volume12,225,953
Avg. Volume8,337,903
Market Cap192.045B
Beta (3Y Monthly)0.98
PE Ratio (TTM)148.89
EPS (TTM)0.49
Earnings DateOct 25, 2018
Forward Dividend & Yield1.92 (2.67%)
Ex-Dividend Date2018-09-14
1y Target Est76.52
Trade prices are not sourced from all markets
  • Why Merck's Latest Success Means Trouble for Exelixis Inc.
    Motley Fool51 minutes ago

    Why Merck's Latest Success Means Trouble for Exelixis Inc.

    Selling Cabometyx to an important group of patients is about to get even more difficult.

  • ACCESSWIRE1 hour ago

    Today's Research Reports on Trending Tickers: Merck & Co., and Bristol-Myers Squibb

    NEW YORK, NY / ACCESSWIRE / October 19, 2018 / U.S. equities plunged on Thursday as worries over global growth weighed on the broader market and investors continued to digest the minutes from the Federal ...

  • The Wall Street Journal16 hours ago

    Jim Scholefield Leaves Nike for Top Tech and Digital Job at Merck

    Jim Scholefield is leaving as Nike Inc.’s global CIO to join Merck & Co. as chief information and digital officer, effective Oct. 29. Mr. Scholefield will lead Merck’s information technology and digital strategy, the pharmaceutical company said in a statement Wednesday.

  • Analyzing Pfizer’s Stock Performance in October
    Market Realist20 hours ago

    Analyzing Pfizer’s Stock Performance in October

    Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.

  • Reutersyesterday

    Merck, Pfizer combo treatment meets main goals of kidney cancer trial

    The combination resulted in statistically significant and clinically meaningful improvements in overall survival of the patients and helped patients survive without the cancer worsening, when compared to Pfizer's kidney cancer drug, Sutent. Keytruda is a blockbuster medicine that targets a blockade of proteins known as PD-1 and is approved for a range of other cancers, including lung cancer.

  • Reutersyesterday

    Merck, Pfizer combo treatment meets main goals of kidney cancer trial

    Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer. The combination resulted in statistically significant and clinically meaningful improvements in overall survival of the patients and helped patients survive without the cancer worsening, when compared to Pfizer's kidney cancer drug, Sutent.

  • Business Wireyesterday

    Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma

    KEYTRUDA is First Anti-PD-1 Therapy in Combination to Improve Both OS and PFS in Advanced or Metastatic RCC, the Most Common Type of Kidney Cancer

  • 2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
    Motley Fool2 days ago

    2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report

    Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.

  • They tackled chronic cough. Now with $54.5 million, this duo is targeting Alzheimer's and more
    American City Business Journals2 days ago

    They tackled chronic cough. Now with $54.5 million, this duo is targeting Alzheimer's and more

    After taking a Peninsula startup through a billion-dollar acquisition, Kathy Glaub and Anthony Ford are at it again. The duo are leading CuraSen Theraepeutics Inc., which said Wednesday that it had raised $54.5 million to target Alzheimer's disease, Parkinson's disease and other, less-common neurodegenerative diseases. The Series A round was led by New Leaf Venture Partners and included Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Pappas Capital and Johnson & Johnson's corporate venture arm.

  • Business Wire2 days ago

    Merck Announces Appointment of Jim Scholefield as Chief Information and Digital Officer

    Merck (MRK), known as MSD outside the United States and Canada, today announced the appointment of Jim Scholefield as chief information and digital officer, effective Oct. 29, 2018. Scholefield will be responsible for leading Merck’s information technology and digital strategy and will be a member of the company’s Executive Committee.

  • Investopedia2 days ago

    5 Blue Chip Drug Stocks Poised for Long-Term Gains

    Big pharmaceutical stocks have routinely lagged those of the biotech sector and, so far this year, are underperforming the broader health-care sector by a margin of more than 7%. Citing fading headwinds along with innovation and boosted new-drug sales, Guggenheim’s Seamus Fernandez names Merck & Co. Inc. ( MRK), Allergan PLC ( AGN) and AstraZeneca ( AZN) as three of his favorites, while also giving Eli Lilly & Co. ( LLY) and Novo Nordisk ( NVO) a buy rating, according to Barron’s.

  • Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional
    Yahoo Finance3 days ago

    Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional

    The Trump new administration's proposal to require prescription drug manufacturers to disclose prices in TV ads may be primed for legal challenges.

  • AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
    Zacks3 days ago

    AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status

    AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.

  • What Nektar Therapeutics’ Valuation Trend Indicates
    Market Realist3 days ago

    What Nektar Therapeutics’ Valuation Trend Indicates

    In October, ten analysts are covering Nektar Therapeutics (NKTR) stock. Eight of them have given the stock a “buy” or higher rating, and two have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $89.38, implying an upside potential of 82.1% over its closing price of $49.08 on October 15.

  • Analyzing Nektar Therapeutics’ Operational Performance
    Market Realist3 days ago

    Analyzing Nektar Therapeutics’ Operational Performance

    Nektar Therapeutics’ (NKTR) cost of goods sold was $5.52 million in the second quarter of 2018 compared to $8.99 million in the second quarter of 2017.

  • Business Wire3 days ago

    U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation for Pancreatic Cancer

    Fourth Orphan Drug Designation in the U.S. for AstraZeneca and Merck’s LYNPARZA

  • The Wall Street Journal3 days ago

    [$$] European Corporate News Roundup

    A $900 million disposal by Spain’s Iberdrola and a revenue warning from British American Tobacco are the corporate highlights in Europe on Tuesday.

  • Merck’s Operating Expenditure and Recent Developments
    Market Realist4 days ago

    Merck’s Operating Expenditure and Recent Developments

    Merck’s (MRK) M&P (materials and production) expenses grew ~10% YoY (year-over-year) to $3.4 billion in the second quarter of 2018, while its M&A (marketing and administrative) expenses were flat YoY at $2.5 billion. The company’s R&D (research and development) expenses grew ~28% YoY to $2.3 billion from $1.8 billion, and its restricting expenditure grew 37% YoY to $228.0 million from $166.0 million. Analysts expect Merck to report non-GAAP M&P expenses of $2.7 billion in the third quarter, and non-GAAP R&D expenses of $2.0 billion.

  • Merck Is Expected to Record Steady Revenue Growth in Q3
    Market Realist4 days ago

    Merck Is Expected to Record Steady Revenue Growth in Q3

    Merck has announced it will be presenting its third-quarter revenue and earnings results on October 25. Analysts expect Merck to report revenue of $10.9 billion, primarily supported by Keytruda label expansions, Bridion, and its vaccine portfolio.

  • Novartis in Q3 2018: Analysts Expect Revenue Growth
    Market Realist4 days ago

    Novartis in Q3 2018: Analysts Expect Revenue Growth

    Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018. There has been operating revenue growth for all three of its segments in the quarter. Analysts expect Novartis’s Innovative Medicines segment to report revenue growth in the third quarter of 2018 compared to the third quarter of 2017.

  • This is Why Merck (MRK) is a Great Dividend Stock
    Zacks4 days ago

    This is Why Merck (MRK) is a Great Dividend Stock

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

  • What Vertex Pharmaceuticals’ Valuation Trend Indicates
    Market Realist7 days ago

    What Vertex Pharmaceuticals’ Valuation Trend Indicates

    In October, there are 24 analysts covering Vertex Pharmaceuticals (VRTX) stock. Twenty of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.83 with a target price of $198.27, implying an upside potential of 12.9% over Vertex Pharmaceuticals’ closing price of $175.66 on October 11.

  • 3 Large-Cap Pharma Stocks Performing Better Than Industry
    Zacks7 days ago

    3 Large-Cap Pharma Stocks Performing Better Than Industry

    We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.

  • Is This the Right Time to Enter Dow? 4 Great Picks
    Zacks7 days ago

    Is This the Right Time to Enter Dow? 4 Great Picks

    A glimpse at the 30-stock blue-chip index will reveal that the recent meltdown is likely to be transitory and can provide a good entry point for investors.

  • Government wants drug companies to disclose prices on TV ads
    Yahoo Finance Video3 days ago

    Government wants drug companies to disclose prices on TV ads

    New regulation could force drug companies to disclose their prices on TV ads. Yahoo Finance's Seana Smith, Zack Guzman and Sibile Marcellus discuss.